Eli Lilly and Company (NYSE:LLY) is Cozad Asset Management Inc.’s 10th Largest Position

Cozad Asset Management Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,066 shares of the company’s stock after purchasing an additional 2,193 shares during the period. Eli Lilly and Company makes up approximately 1.5% of Cozad Asset Management Inc.’s investment portfolio, making the stock its 10th biggest position. Cozad Asset Management Inc.’s holdings in Eli Lilly and Company were worth $16,005,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LLY. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares during the last quarter. Quent Capital LLC lifted its stake in Eli Lilly and Company by 5.3% in the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares during the last quarter. W.H. Cornerstone Investments Inc. boosted its position in shares of Eli Lilly and Company by 44.6% during the first quarter. W.H. Cornerstone Investments Inc. now owns 1,213 shares of the company’s stock valued at $944,000 after buying an additional 374 shares during the period. Manchester Capital Management LLC boosted its position in shares of Eli Lilly and Company by 33.9% during the first quarter. Manchester Capital Management LLC now owns 4,049 shares of the company’s stock valued at $3,150,000 after buying an additional 1,025 shares during the period. Finally, Advisory Services Network LLC boosted its position in shares of Eli Lilly and Company by 5.1% during the first quarter. Advisory Services Network LLC now owns 45,528 shares of the company’s stock valued at $35,418,000 after buying an additional 2,225 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Barclays dropped their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $776.47 on Thursday. The company has a market capitalization of $737.11 billion, a price-to-earnings ratio of 83.94, a price-to-earnings-growth ratio of 3.05 and a beta of 0.43. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average of $901.75 and a 200 day moving average of $867.32.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.